Suven Life Sciences Limited (BOM:530239)
India
· Delayed Price · Currency is INR 289.35
+13.75 (4.99%)
At close: Jul 14, 2025
Suven Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 66.56 | 116.93 | 135.39 | 118.44 | 134.78 | Upgrade
|
Other Revenue | - | - | 0.56 | 1.06 | 5.95 | Upgrade
|
| 66.56 | 116.93 | 135.95 | 119.51 | 140.73 | Upgrade
| |
Revenue Growth (YoY) | -43.08% | -13.99% | 13.76% | -15.08% | -4.30% | Upgrade
|
Cost of Revenue | - | 8.24 | 5.66 | 24.33 | 1.03 | Upgrade
|
Gross Profit | 66.56 | 108.69 | 130.29 | 95.18 | 139.7 | Upgrade
|
Selling, General & Admin | 208.25 | 190.24 | 186.21 | 210.21 | 185.36 | Upgrade
|
Research & Development | 1,440 | 1,144 | 1,154 | 1,064 | 710.27 | Upgrade
|
Other Operating Expenses | 76.43 | 52.08 | 45.56 | 39.53 | 33.45 | Upgrade
|
Operating Expenses | 1,783 | 1,452 | 1,451 | 1,357 | 972.55 | Upgrade
|
Operating Income | -1,716 | -1,343 | -1,320 | -1,262 | -832.85 | Upgrade
|
Interest Expense | -0.47 | -1.58 | -2.89 | -5.32 | -8.15 | Upgrade
|
Interest & Investment Income | - | 164.25 | 64.16 | 11.26 | 69.79 | Upgrade
|
Currency Exchange Gain (Loss) | - | -0.7 | -3.28 | -3.71 | -4.14 | Upgrade
|
Other Non Operating Income (Expenses) | 108.97 | 0 | - | 0 | - | Upgrade
|
EBT Excluding Unusual Items | -1,607 | -1,181 | -1,262 | -1,260 | -775.35 | Upgrade
|
Gain (Loss) on Sale of Investments | - | 45.49 | 17.92 | 3.56 | 0.61 | Upgrade
|
Asset Writedown | - | - | -0.02 | -0.86 | - | Upgrade
|
Other Unusual Items | - | 0.11 | 1.85 | 0.13 | - | Upgrade
|
Pretax Income | -1,607 | -1,061 | -1,183 | -1,220 | -774.74 | Upgrade
|
Income Tax Expense | - | -10.02 | - | - | -53.23 | Upgrade
|
Net Income | -1,607 | -1,051 | -1,183 | -1,220 | -721.51 | Upgrade
|
Net Income to Common | -1,607 | -1,051 | -1,183 | -1,220 | -721.51 | Upgrade
|
Shares Outstanding (Basic) | 218 | 218 | 178 | 135 | 127 | Upgrade
|
Shares Outstanding (Diluted) | 218 | 218 | 178 | 135 | 127 | Upgrade
|
Shares Change (YoY) | 0.01% | 22.31% | 32.29% | 5.88% | - | Upgrade
|
EPS (Basic) | -7.37 | -4.82 | -6.63 | -9.05 | -5.67 | Upgrade
|
EPS (Diluted) | -7.37 | -4.82 | -6.63 | -9.05 | -5.67 | Upgrade
|
Free Cash Flow | -1,914 | -1,155 | -1,189 | -1,473 | -1,023 | Upgrade
|
Free Cash Flow Per Share | -8.78 | -5.29 | -6.67 | -10.93 | -8.04 | Upgrade
|
Dividend Per Share | - | - | - | 1.000 | - | Upgrade
|
Gross Margin | 100.00% | 92.95% | 95.84% | 79.64% | 99.27% | Upgrade
|
Operating Margin | -2578.13% | -1148.50% | -971.27% | -1056.14% | -591.80% | Upgrade
|
Profit Margin | -2415.11% | -898.63% | -869.95% | -1020.82% | -512.69% | Upgrade
|
Free Cash Flow Margin | -2875.39% | -987.51% | -874.42% | -1232.64% | -727.12% | Upgrade
|
EBITDA | -1,663 | -1,285 | -1,262 | -1,227 | -797.75 | Upgrade
|
D&A For EBITDA | 53.07 | 57.89 | 58 | 35.41 | 35.09 | Upgrade
|
EBIT | -1,716 | -1,343 | -1,320 | -1,262 | -832.85 | Upgrade
|
Revenue as Reported | 175.53 | 328.23 | 219.88 | 134.46 | 212.32 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.